Want to see FR:ALINS full AI Analyst Report?
ALINS Stock Chart & Stats
€0.23
>-€0.01(-3.61%)
At close: 4:00 PM EST
€0.23
>-€0.01(-3.61%)
Day’s Range― - ―
52-Week Range€0.19 - €0.43
Previous CloseN/A
Volume1.10K
Average Volume (3M)21.02K
Market Cap
€12.67M
Enterprise Value€12.13M
Total Cash (Recent Filing)€1.44M
Total Debt (Recent Filing)€1.37M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Jul 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding52,806,030
10 Day Avg. Volume15,382
30 Day Avg. Volume21,018
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)7.33
Price to Sales (P/S)5.40
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€6.96M
Bulls Say, Bears Say
Bulls Say
Recurring Subscription ModelA subscription-based licensing model creates recurring revenue and service relationships with healthcare institutions. Over months this improves revenue predictability, supports multi-year customer retention, and can enable more stable cash flow to fund product development and support investments.
Focused Imaging Software PortfolioSpecialization in advanced medical imaging positions the company in a niche with durable demand from radiology workflows. Domain-focused products can create higher switching costs, clinical integration advantages, and sustained adoption by hospitals and imaging centers over a multi-quarter horizon.
Top-line Growth MetricReported revenue growth of about 13.6% signals improving sales momentum. If sustained alongside the subscription model, this growth can compound recurring revenue, improve operational leverage and margins over several quarters, reducing dependency on external financing for operations.
Bears Say
Negative Margins And Operating LossesNegative gross and net margins and persistent operating losses indicate the core business is not yet profitable. Over months this erodes reserves, limits reinvestment capacity, and makes breakeven harder to reach without sustained margin improvement or cost structure changes.
High Leverage And Weak Equity BaseA high debt-to-equity ratio and low equity ratio reduce financial flexibility and raise refinancing risk. Over the medium term this can increase interest burdens, constrain R&D and commercialization spending, and make the company more vulnerable to adverse funding conditions.
Negative Operating And Free Cash FlowNegative operating and free cash flow point to ongoing cash burn and weak cash generation. Over several months this typically necessitates external financing or cost cuts, which can dilute shareholders or constrain growth investments and jeopardize long-term product rollouts.
Intrasense SA News
ALINS FAQ
What was Intrasense SA’s price range in the past 12 months?
Intrasense SA lowest stock price was €0.19 and its highest was €0.43 in the past 12 months.
What is Intrasense SA’s market cap?
Intrasense SA’s market cap is €12.67M.
When is Intrasense SA’s upcoming earnings report date?
Intrasense SA’s upcoming earnings report date is Jul 09, 2026 which is in 3 days.
How were Intrasense SA’s earnings last quarter?
Intrasense SA released its earnings results on Mar 11, 2026. The company reported -€0.151 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.151.
Is Intrasense SA overvalued?
According to Wall Street analysts Intrasense SA’s price is currently Overvalued.
Does Intrasense SA pay dividends?
Intrasense SA does not currently pay dividends.
What is Intrasense SA’s EPS estimate?
Intrasense SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intrasense SA have?
Intrasense SA has 52,806,030 shares outstanding.
What happened to Intrasense SA’s price movement after its last earnings report?
Intrasense SA reported an EPS of -€0.151 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.823%.
Which hedge fund is a major shareholder of Intrasense SA?
Currently, no hedge funds are holding shares in FR:ALINS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intrasense SA
Established in 2004 and headquartered in Montpellier, France, Intrasense S.A. specializes in the global development of sophisticated software for visualizing and analyzing diverse medical imaging data, marketed under its Myrian brand. The company's offerings feature the Myrian Imaging Layer, a versatile multi-modality visualization platform tailored for professionals in the health industry. It also provides Myrian Studio, a dedicated development environment empowering innovators, industrial partners, spin-offs, and research institutions to build medical imaging applications. Furthermore, Intrasense leverages its Myrian technologies to facilitate the creation of biomarkers and artificial intelligence solutions. A key component of its product line is Myrian Clinical Apps, an extensive collection of advanced post-processing clinical applications. This portfolio encompasses specialized modules like Myrian XP-Breast, XP-Prostate, XP-Liver, XP-Mammo, XP-Lung, XP-Colon, XP-Vessel, and XP-Cardiac, alongside Myrian XL-Onco for tracking lesions. These applications, which also provide solutions for analyzing specific pathologies or organs, offer various tools for interpreting data from MRI, CT scans, conventional radiology, and nuclear imaging examinations.
Technical Analysis
Cegedim
―
Theraclion SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―